The Comparability of Bispectral Index and Neurosense During Anesthesia
This study has been terminated.
(Differences between BIS and Neurosense are important. This study can be terminated.)
Sponsor:
Hopital Foch
Information provided by:
Hopital Foch
ClinicalTrials.gov Identifier:
NCT00910416
First received: May 27, 2009
Last updated: January 22, 2011
Last verified: January 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The assessment of anesthesia depth was based, until recently, on the evolution of hemodynamic parameters. Nowadays it can be evaluated by several monitoring methods, derived from electroencephalogram analysis, namely the Bispectral Index (Aspect Medical Systems, Newton, USA). A new modality is currently under development: the NeuroSENSE (Cleveland Medical Devices Inc., Cleveland, OH 44103, USA). The goal of this study is to compare both monitoring modalities during anesthesia.
| Condition | Intervention |
|---|---|
|
Anesthesia |
Drug: propofol, remifentanil, atracurium Drug: propofol, remifentanil, atracurium, sevoflurane Device: EEG monitoring |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | The Comparability of Bispectral Index and Neurosense During Total Intravenous Anesthesia and Balanced Anesthesia |
Resource links provided by NLM:
Further study details as provided by Hopital Foch:
Primary Outcome Measures:
- Concordance between pairs of Bispectral Index and Neurosense indices during maintenance of anesthesia [ Time Frame: at the end of each case ] [ Designated as safety issue: No ]Statistical analysis of concordance
Secondary Outcome Measures:
- Concordance between pairs of Bispectral Index and Neurosense indices during induction and emergence [ Time Frame: at the end of each case ] [ Designated as safety issue: No ]Statistical analysis of concordance
| Estimated Enrollment: | 200 |
| Study Start Date: | May 2009 |
| Study Completion Date: | December 2010 |
| Primary Completion Date: | December 2010 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
| patients receiving iv anesthesia |
Drug: propofol, remifentanil, atracurium
propofol, remifentanil, atracurium dosages are adapted according to clinician's judgment
Device: EEG monitoring
simultaneous monitoring with Bis and Neurosense
|
| patients receiving balanced anesthesia |
Drug: propofol, remifentanil, atracurium, sevoflurane
dosages are adapted according to clinician's judgment
Device: EEG monitoring
simultaneous monitoring with Bis and Neurosense
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
Surgical patients
Criteria
Inclusion Criteria:
- Patients requiring either intravenous anesthesia or balanced anesthesia (including sevoflurane)
Exclusion Criteria:
- Pregnant women,
- Allergy to propofol, remifentanil, morphine, muscle relaxant, or to a component,
- Hypersensibility to sufentanil, remifentanil or to a derivate of fentanyl,
- History of neurological disorder or central brain lesion, of muscle disease,
- Patient carrying a pacemaker,
- Patients receiving a psychotropic treatment or a morphine agonist-antagonist,
- Alcoholic patients and patients taking opiates,
- Surgery with extracorporeal circulation,
- Surgical position incompatible with an adequate positioning of the probe.
Contacts and Locations
More Information
Publications:
| Responsible Party: | Pr Marc Fischler, Hopital Foch |
| ClinicalTrials.gov Identifier: | NCT00910416 History of Changes |
| Other Study ID Numbers: | 2008/22 |
| Study First Received: | May 27, 2009 |
| Last Updated: | January 22, 2011 |
| Health Authority: | France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis) |
Keywords provided by Hopital Foch:
|
Anesthesia Monitoring, Intraoperative Electroencephalography/*drug effects |
Additional relevant MeSH terms:
|
Anesthetics Propofol Sevoflurane Remifentanil Atracurium Central Nervous System Depressants Physiological Effects of Drugs Pharmacologic Actions Central Nervous System Agents Therapeutic Uses Nicotinic Antagonists Cholinergic Antagonists Cholinergic Agents Neurotransmitter Agents |
Molecular Mechanisms of Pharmacological Action Neuromuscular Nondepolarizing Agents Neuromuscular Blocking Agents Neuromuscular Agents Peripheral Nervous System Agents Anesthetics, Intravenous Anesthetics, General Hypnotics and Sedatives Platelet Aggregation Inhibitors Hematologic Agents Anesthetics, Inhalation Analgesics, Opioid Analgesics Sensory System Agents |
ClinicalTrials.gov processed this record on May 16, 2013